TITLE

Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial

AUTHOR(S)
Nobili, Valerio; Bedogni, Giorgio; Alisi, Anna; Pietrobattista, Andrea; Ris⇔(c), Patrizia; Galli, Claudio; Agostoni, Carlo
PUB. DATE
April 2011
SOURCE
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Apr2011, Vol. 96 Issue 4, p350
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective To investigate whether dietary supplementation with docosahexaenoic acid (DHA) decreases liver fat content in children with non-alcoholic fatty liver disease (NAFLD). Design, setting and patients We performed a randomised controlled trial of DHA supplementation (250 and 500 mg/day) versus placebo in 60 children with biopsy-proven NAFLD (20 children per group). Main outcome measures The main outcome was the change in liver fat content as detected by ultrasonography after 6 months of treatment. Secondary outcomes were the changes in insulin sensitivity index, alanine transaminase, triglycerides and body mass index after 6 months of treatment. Results Blood DHA increased in children supplemented with DHA (0.65%, 95% CI 0.30% to 1.10% for the DHA 250 mg group and 1.15%, 0.87% to 1.43% for the DHA 500 mg group). The odds of more severe versus less severe liver steatosis after treatment was lower in children treated with DHA 250 mg/day (OR = 0.01, 0.002 to 0.11, p <0.001) and DHA 500 mg/day (OR = 0.04, 0.002 to 0.46, p = 0.01) as compared to placebo but there was no difference between the DHA groups (p = 0.4). Insulin sensitivity index increased and triglycerides decreased to a similar degree in both DHA groups as compared to placebo but there was no effect on alanine transaminase and body mass index. Conclusion DHA supplementation improves liver steatosis and insulin sensitivity in children with NAFLD.
ACCESSION #
61211336

 

Related Articles

  • Erratum to: Specific Features of Analgesic Effect of Docosahexaenoic Acid in Rats with Neuropathic Pain Syndrome. Dyuizen, I.; Manzhulo, I.; Ogurtsova, O.; Lamash, N.; Latyshev, N.; Kas'yanov, S. // Bulletin of Experimental Biology & Medicine;Apr2014, Vol. 156 Issue 6, p885 

    A correction to the article "Specific Features of Analgesic Effect of Docosahexaenoic Acid in Rats with Neuropathic Pain Syndrome" that was published in the March 2014 issue is presented.

  • Insulin sensitivity indices: fasting versus glucose-stimulated indices in pediatric non-alcoholic fatty liver disease. OZHAN, B.; ERSOY, B.; KIREMITCI, S.; OZKOL, M.; TANELI, F. // European Review for Medical & Pharmacological Sciences;2015, Vol. 19 Issue 18, p3450 

    OBJECTIVE: We aimed to compare insulin sensitivity indices, fasting vs glucose stimulated, in children and adolescents with non-alcoholic fatty liver disease. PATIENTS AND METHODS: Two hundred-eleven obese children with median age of 11.24 ± 2.65 years were evaluated. After initial clinical...

  • Healthy Fat Helps Kids Sleep Longer, Better.  // Better Nutrition;Jun2014, Vol. 76 Issue 6, p10 

    The article discusses the study related to supplements of Docosahexaenoic acid (DHA), one of the key omega-3 fatty acids which improve sleep including DHA supplement is made from algae and also found in fish oil and link of sleep problems with low levels of omega-3 fatty acid.

  • Maternal DHA supplements may help premature infants get necessary nutrients.  // Infectious Diseases in Children;Jun2010, Vol. 23 Issue 6, p30 

    The article reports that mothers who breast-feed should take docosahexaenoic acid (DFA) supplements to give premature infants the nutrition they need, according to speakers at the Pediatric Academic Societies Meeting held in Vancouver, British Columbia, from May 1 to 4, 2010.

  • DHA Fails to Treat Alzheimer's in JAMA-Published Study.  // Nutraceuticals World;Dec2010, Vol. 13 Issue 10, p18 

    The article focuses on a study published in the "Journal of the American Medical Association" (JAMA) which showed the failure of docosahexaenoic acid (DHA) to slow the cognitive and functional decline in patients with mild to moderate Alzheimer's disease.

  • DHA Helps Preserve Brain Volume. Dye, D. // Life Extension;Jun2012, Vol. 18 Issue 6, p1 

    No abstract available.

  • GOED Submits Authorized Health Claim Petition to FDA.  // Nutraceuticals World;Dec2013, Vol. 16 Issue 10, p20 

    The article reports on the petition submitted by the Global Organization for EPA and DHA Omega-3s (GOED) to the U.S. Food and Drug Administration (FDA) for an authorized health claim for Eicosapentaenoic and Docosahexaenoic Acids and reduction of blood pressure in the general population.

  • Boomers can take action for future brain health.  // South Asian Post;5/8/2014, p10 

    The article provides tips to keep brain healthy for baby boomers, and mentions factors like maintaining a diet including docosahexaenoic acid (DHA) omega-3, vitamin E, and lutein, presents the views of Michael Roizen, co-founder of health information provider Real Age, on the same.

  • Docosahexaenoic Acid Supplementation and Alzheimer Disease. Umhau, John C.; Quinn, Joseph F.; Aisen, Paul S. // JAMA: Journal of the American Medical Association;2/16/2011, Vol. 305 Issue 7, p672 

    A letter to the editor is presented about a study on the effect of docosahexaenoic acid supplementation on Alzheimer's disease.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics